Elicio Therapeutics (ELTX) Institutional Ownership $9.95 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.98 +0.03 (+0.25%) As of 05/22/2026 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Elicio Therapeutics (NASDAQ:ELTX)CurrentInstitutional OwnershipPercentage35.03%Number ofInstitutional Buyers(last 12 months)21TotalInstitutional Inflows(last 12 months)$5.57MNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$636.61K Get ELTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Elicio Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data ELTX Institutional Buying and Selling by Quarter Elicio Therapeutics Major Shareholders & Ownership History ExportReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2026 Bank of America Corp DE15,333$164K0.0%+1,225.2%0.080% 5/15/2026 OMERS ADMINISTRATION Corp10,700$114K0.0%-54.5%0.056% 5/14/2026 Renaissance Technologies LLC121,631$1.30M0.0%+332.7%0.637% 4/27/2026 HB Wealth Management LLC10,463$112K0.0%N/A0.057% 2/18/2026 Quadrature Capital Ltd17,159$137K0.0%N/A0.098% 2/18/2026 Occudo Quantitative Strategies LP15,827$126K0.0%N/A0.090% 2/18/2026 Balyasny Asset Management L.P.138,762$1.11M0.0%-6.3%0.793% 2/18/2026 683 Capital Management LLC56,442$449K0.0%N/A0.323% 2/16/2026 Squarepoint Ops LLC16,662$133K0.0%N/A0.095% 2/16/2026 OMERS ADMINISTRATION Corp23,500$187K0.0%N/A0.134% Get the Latest News and Ratings for ELTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/13/2026 Marshall Wace LLP117,200$933K0.0%+35.4%0.670% 2/13/2026 State Street Corp46,300$369K0.0%+20.9%0.265% 2/13/2026 Summit Financial LLC10,010$80K0.0%N/A0.057% 2/12/2026 Renaissance Technologies LLC28,111$224K0.0%-42.2%0.161% 2/9/2026 Geode Capital Management LLC132,518$1.06M0.0%+2.2%0.758% 2/9/2026Jefferies Financial Group Inc.11,942$95K0.0%-40.9%0.068% 2/6/2026 HighTower Advisors LLC11,186$89K0.0%N/A0.064% 2/2/2026 CM Management LLC25,000$199K0.2%+316.7%0.143% 11/21/2025 CIBC Bancorp USA Inc.32,000$350K0.0%N/A0.183% 11/17/2025 Susquehanna International Group LLP120,207$1.32M0.0%+606.1%0.687% 11/17/2025 Millennium Management LLC22,846$250K0.0%N/A0.131% 11/17/2025 Bank of America Corp DE3,585$39K0.0%+186.8%0.020% 11/13/2025 CM Management LLC6,000$66K0.1%-76.0%0.037% 11/12/2025 Cresset Asset Management LLC26,925$295K0.0%N/A0.165% 11/7/2025Vanguard Group Inc.473,859$5.18M0.0%+4.2%2.900% 8/14/2025 Raymond James Financial Inc.6,000$46K0.0%N/A0.037% 8/8/2025 Geode Capital Management LLC120,831$933K0.0%+56.0%0.755% 8/4/2025 Mayflower Financial Advisors LLC10,000$77K0.0%N/A0.063% 5/19/2025Jane Street Group LLC14,993$92K0.0%N/A0.139% 5/15/2025Royal Bank of Canada36,537$225K0.0%N/A0.339% 5/9/2025CM Management LLC55,000$339K0.3%+37.5%0.510% 4/28/2025Moody Lynn & Lieberson LLC10,000$62K0.0%N/A0.093% 2/7/2025CM Management LLC40,000$204K0.2%-20.0%0.371% 8/15/2024Armistice Capital LLC100,000$411K0.0%N/A0.978% 8/9/2024Warberg Asset Management LLC11,801$49K0.0%N/A0.115% 8/2/2024CM Management LLC50,000$206K0.2%-33.3%0.489% 5/14/2024CM Management LLC75,000$570K0.5%+50.0%0.733% 8/4/2023CM Management LLC65,000$618K0.6%N/A2.159% ELTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ELTX shares? During the previous two years, 28 institutional investors and hedge funds held shares of Elicio Therapeutics. The most heavily invested institutionals were Vanguard Group Inc. ($5.18M), Susquehanna International Group LLP ($1.32M), Renaissance Technologies LLC ($1.30M), Balyasny Asset Management L.P. ($1.11M), Geode Capital Management LLC ($1.06M), Marshall Wace LLP ($933K), and 683 Capital Management LLC ($449K).Learn more on Elicio Therapeutics' institutional investors. What percentage of Elicio Therapeutics' stock is owned by institutional investors? 35.03% of Elicio Therapeutics' stock is owned by institutional investors. Learn more on ELTX's institutional investor holdings. Which institutional investors have been buying Elicio Therapeutics' stock? Of the 26 institutional investors that purchased Elicio Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Susquehanna International Group LLP ($103.18K), Armistice Capital LLC ($100K), Renaissance Technologies LLC ($93.52K), 683 Capital Management LLC ($56.44K), Geode Capital Management LLC ($46.20K), Royal Bank of Canada ($36.54K), and CM Management LLC ($34K). How much institutional buying is happening at Elicio Therapeutics? Institutional investors have bought a total of 595,338 shares in the last 24 months. This purchase volume represents approximately $5.57M in transactions. Which of Elicio Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Elicio Therapeutics stock in the last 24 months: Renaissance Technologies LLC ($20.56K), CM Management LLC ($19K), OMERS ADMINISTRATION Corp ($12.80K), Balyasny Asset Management L.P. ($9.31K), and Jefferies Financial Group Inc. ($8.26K). How much institutional selling is happening at Elicio Therapeutics? Institutional investors have sold a total of 69,932 shares in the last 24 months. This volume of shares sold represents approximately $636.61K in transactions. Related Companies ABUS Institutional Ownership ETON Institutional Ownership KURA Institutional Ownership ABSI Institutional Ownership DRUG Institutional Ownership IVA Institutional Ownership CERT Institutional Ownership ANRO Institutional Ownership SLDB Institutional Ownership GYRE Institutional Ownership This page (NASDAQ:ELTX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is...Brownstone Research | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.